Friday 6 November 2026 Export SNGX’s income statement to Excel — free account

Soligenix Inc.

SNGX Healthcare Biotechnology

Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023.

EPS: +85.4%
Free cash flow: +37.8%

Quarter to June 2026, against a year earlier

0.34 0.01 +3.03%

Follow SNGX

Alert me

Market cap: $7.3M
P/E: 0.0×
Fwd P/E: −0.5×
Dividend yield: —
F-score: n/a
Altman Z: −38.91
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 7.26

Revenue ttm 0.49

Net income ttm (10.24)

Free cash flow ttm (9.74)

Net debt Q (9.81)

Valuation

P/E 0.00

Forward P/E (0.53)

Price / sales 10.97

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.82

Financial health

Current ratio Q 2.77

Debt / equity Q 0.00

Interest coverage Q 192.60

Growth

Revenue growth Q −98.89%

Operating income growth Q +24.04%

EPS, this year +81.31%

EPS, next year A +37.50%

Revenue, next year A +318.76%

EPS, past 5 yrs —

EPS, next 5 yrs A +48.16%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 58.89%

10-year low 10-year high

P/B against its own 10 years 3.39%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	8	8	8	10
Receivables	0	—	—	—
Inventory	—	—	—	—
Other	—	0	0	0
	10	9	9	10

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	2	1	—	—
Other	—	—	—	—
	6	5	4	4

Compound Annual Growth %

	10y	5y	3y
Sales	(33.48%)	(51.88%)	(47.48%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	7.18%	0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.22 Actual −0.12

−0.92 −0.70 −0.47 −0.24 −0.02

Q2 FY25 Miss −0.03

Q3 FY25 Beat +0.05

Q1 FY26 Beat +0.02

Q2 FY26 Beat +0.10

Q3 FY26 — Nov 6

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q2 FY25	−0.79	−0.82	Miss by 0.03
Q3 FY25	−0.63	−0.58	Beat by 0.05
Q1 FY26	−0.30	−0.28	Beat by 0.02
Q2 FY26	−0.22	−0.12	Beat by 0.10
Q3 FY26	−0.12	—	Reports 6 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.28)	(0.12)	—	—	—
’25	(0.97)	(0.82)	(0.58)	(0.29)	(2.14)
’24	(2.88)	(1.31)	(0.78)	(1.14)	(4.98)
’23	(5.76)	(3.52)	(2.56)	(2.78)	(12.64)
’22	(23.99)	(14.39)	(19.19)	(20.82)	(76.96)
’21	(14.39)	(11.99)	(21.59)	(26.39)	(74.36)
’20	(76.76)	(23.99)	(14.39)	(45.58)	(153.52)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	0	0	—	—	0
’23	0	0	0	0	1
’22	0	0	0	0	1
’21	0	0	0	0	1
’20	1	1	1	0	2
’19	1	2	1	1	5

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(2)	(3)	(3)	(3)	(10)
’24	(1)	(2)	(3)	(2)	(8)
’23	(2)	(2)	(3)	(2)	(9)
’22	(3)	(3)	(3)	(4)	(13)
’21	(4)	(2)	(3)	(3)	(12)
’20	(3)	(2)	(3)	(4)	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(2)	(3)	(3)	(3)	(10)
’24	(1)	(2)	(3)	(2)	(8)
’23	(2)	(2)	(3)	(2)	(9)
’22	(3)	(3)	(3)	(4)	(13)
’21	(4)	(2)	(3)	(3)	(12)
’20	(3)	(2)	(3)	(4)	(11)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	10	5	5	5	2	1	1	1	0	—	0		(42.8%)	2	2	2	0.0%
	Gross margin, %	19.29	20.66	12.28	22.95	22.82	11.60	41.95	11.59	0.00	—	0.00		(19.3) pt	Powerpack Soligenix Inc.’s next three years, line by line Analysts expect revenue to grow 0.0% a year to 2028 — faster than the −42.8% of the last 8 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(4)	(8)	(9)	(10)	(19)	(13)	(15)	(8)	(9)	(12)	(11)		+13.3%
	EBT margin, %	(36.13)	(139.23)	(169.80)	(215.26)	(785.17)	(1,627.53)	(1,575.86)	(942.16)	(7,266.08)	0.00	0.00		+36.1 pt
	Net income	(3)	(7)	(9)	(9)	(18)	(13)	(14)	(6)	(8)	(11)	(10)		+14.6%
Per share, $
Per share, $	Revenue	720.61	212.21	95.47	57.30	20.59	4.93	5.29	1.73	0.07	0.00	0.00		n/m
	Earnings	(223.09)	(279.17)	(163.12)	(115.14)	(153.52)	(74.36)	(76.96)	(12.64)	(4.98)	(2.14)	(1.27)		(40.3%)
	Cash flow	(343.61)	(254.32)	(131.96)	(92.94)	(99.95)	(70.21)	(70.51)	(17.74)	(5.06)	(1.98)	(0.61)		(43.6%)
	Capex	(0.50)	(1.03)	(0.02)	(0.31)	(0.06)	(0.07)	(0.07)	0.00	0.00	0.00	0.00		(49.3%)
	Free cash flow	(344.11)	(255.35)	(131.98)	(93.25)	(100.01)	(70.28)	(70.58)	(17.74)	(5.06)	(1.98)	(0.61)		(43.6%)
	Book value	510.15	246.86	114.39	18.03	32.65	64.13	(13.77)	5.20	2.48	1.02	0.42		(49.9%)
	Shares, m	0	0	0	0	0	0	0	0	2	5	9		+92.2%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	0.00		0.0
	P/S	0.79	2.53	2.16	6.07	14.92	32.14	22.00	7.86	9.06	—	10.97		10.8
	P/B	1.11	2.18	1.80	19.30	9.41	2.47	0.00	2.62	1.09	—	0.82		4.4
	EV/Sales	(0.05)	1.10	0.45	4.93	11.36	12.63	18.60	1.68	(1.93)	—	(4.05)		5.4
	EV/FCF	0.11	(0.91)	(0.32)	(3.03)	(2.34)	(0.89)	(1.39)	(0.16)	0.11	—	0.21		(1.0)
Cash, $m
Cash, $m	Operating cash flow	(5)	(7)	(7)	(8)	(11)	(12)	(13)	(9)	(8)	(10)	(10)		+8.4%
	Capex	0	0	0	0	0	0	0	—	—	0	0		(2.2%)
	Free cash flow	(5)	(7)	(7)	(8)	(11)	(12)	(13)	(9)	(8)	(10)	(10)		+8.4%
Balance, $m
Balance, $m	Working capital	7	6	6	1	13	20	(3)	3	4	5	7		(3.7%)
	Net debt	(9)	(8)	(9)	(5)	(8)	(16)	(3)	(5)	(6)	(8)	(10)		(1.1%)
	Shareholders’ equity	7	6	6	1	4	11	(2)	3	4	5	7		(3.7%)
Returns, %
Returns, %	ROA	(36.77)	(72.13)	(88.82)	(102.43)	(127.87)	(53.68)	(67.06)	(51.01)	(88.11)	(121.75)	(125.95)		(85.0) pt
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0 pt
	ROE	(87.96)	(104.21)	(141.27)	(241.83)	(680.47)	(173.54)	(334.43)	(23,801.16)	(248.98)	(235.50)	(241.65)		(147.5) pt
People
People	Employees	19	18	14	16	18	15	15	15	16	14	—		(3.3%)
	Revenue/emp, $m	0.55	0.30	0.37	0.29	0.13	0.05	0.06	0.06	0.01	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2024 · latest quarter Jun 2024 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TCRT Alaunos Therapeutics, Inc.	$7.6M	— (loss-making)	— (loss-making)	+200.00% (above 0%: growing)	n/m	+57.20% (above 0%: growing)	100.00%	0.00%	Compare
ALZN Alzamend Neuro, Inc.	$7.5M	— (loss-making)	—	—	n/m	+51.82% (above 0%: growing)	0.00%	0.00%	Compare
CLGN CollPlant Biotechnologies Ltd. Sponsored ADR	$7.5M	— (loss-making)	— (loss-making)	−39.66% (below 0%: shrinking)	n/m	+5.08% (above 0%: growing)	(422.22%)	(2,437.96%)	Compare
VTGN VistaGen Therapeutics, Inc.	$7.3M	— (loss-making)	— (loss-making)	+504.92% (above 0%: growing)	n/m	+22.23% (above 0%: growing)	100.00%	(904.34%)	Compare
SNGX Soligenix Inc.	$7.3M	— (loss-making)	— (loss-making)	−98.89% (below 0%: shrinking)	n/m	+37.83% (above 0%: growing)	0.00%	0.00%
XTLB XTL Biopharmaceuticals Ltd.	$7.3M	— (loss-making)	—	−39.32% (below 0%: shrinking)	0.00%	+46.78% (above 0%: growing)	0.00%	0.00%	Compare
ENSC Ensysce Biosciences, Inc.	$7.0M	— (loss-making)	— (loss-making)	−15.10% (below 0%: shrinking)	n/m	+27.50% (above 0%: growing)	100.00%	(221.28%)	Compare
KPRX Kiora Pharmaceuticals, Inc.	$6.6M	— (loss-making)	— (loss-making)	−93.64% (below 0%: shrinking)	n/m	+50.06% (above 0%: growing)	100.00%	0.00%	Compare
CRIS Curis, Inc.	$5.7M	— (loss-making)	— (loss-making)	−65.98% (below 0%: shrinking)	n/m	−20.44% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$7.3M	—	—	−39.32%	—	+37.14%	100.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 3 August 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	1.09m	1.21m	1.00
2024	832.63k	697.45k	2.00
2023	700.48k	531.40k	4.00

Ownership

Directors and executive officers, together 1.91%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Soligenix Inc. (SNGX) Latest News

6 Nov

Impact 3 · 7:30 AM · PR Newswire

Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results

12 Aug

Impact 3 · 7:25 AM

SNGX: Applying for Vaccine Development Funding for Ebola Vaccine

10 Aug

Impact 4 · 7:09 AM · clinicaltrialsarena.com

Soligenix culls topical lymphoma asset after Phase III miss

7 Aug

Impact 3 · 7:30 AM

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

8 Jun

Impact 3 · 7:30 AM · PR Newswire

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

27 May

Impact 3 · 7:28 AM · Stocktwits

SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy

26 May

Impact 3 · 7:30 AM · PR Newswire

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

14 May

Impact 3 · 10:08 AM · Zacks Small Cap Research

SNGX: Continuing to Analyze FLASH2 Data

8 May

Impact 3 · 7:30 AM · PR Newswire

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

29 Apr

Impact 5 · 9:13 AM · Zacks Small Cap Research

SNGX: FLASH2 Trial Recommended to Stop for Futility

28 Apr

Impact 5 · 11:06 AM · InvestorsHub

SNGX Phase 3 Trial Halted — HyBryte Setback Puts Strategy in Question

Impact 4 · 7:30 AM · PR Newswire

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

20 Apr

Impact 4 · 2:23 PM

Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status

17 Apr

Impact 4 · 2:30 PM · NewMediaWire

Soligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study Results

6 Apr

Impact 4 · 11:45 AM · Zacks Small Cap Research

SNGX: Interim Analysis for Phase 3 CTCL Study in 2Q26

2 Apr

Impact 4 · 3:30 PM · NewMediaWire

Soligenix (SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy

Impact 4 · 7:30 AM · PR Newswire

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

1 Apr

Impact 4 · 3:00 PM · NewMediaWire

Soligenix (SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 Results

31 Mar

Impact 3 · 7:30 AM · PR Newswire

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

26 Mar

Impact 4 · 3:30 PM · NewMediaWire

Soligenix (SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behcet Disease

Impact 4 · 7:30 AM · PR Newswire

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

25 Mar

Impact 3 · 2:45 PM · NewMediaWire

Soligenix (SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach

23 Mar

Impact 4 · 3:30 PM · NewMediaWire

Soligenix (SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

19 Mar

Impact 3 · 3:30 PM · NewMediaWire

Soligenix (SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication

Impact 3 · 7:30 AM · PR Newswire

Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

12 Mar

Impact 4 · 6:06 AM · Zacks Small Cap Research

SNGX: Important Upcoming Readouts in Phase 3 CTCL Study

10 Mar

Impact 4 · 3:15 PM · NewMediaWire

Soligenix (SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behcet Disease

Impact 4 · 7:30 AM · PR Newswire

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

6 Mar

Impact 4 · 12:00 PM · NewMediaWire

Soligenix (SNGX) Leverages Platform Science for Broader Therapeutic Reach

26 Feb

Impact 4 · 7:30 AM · PR Newswire

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Soligenix Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 3 August 2026

Chief executive’s pay

Ownership

Soligenix Inc. (SNGX) Latest News

6 Nov

12 Aug

10 Aug

7 Aug

8 Jun

27 May

26 May

14 May

8 May

29 Apr

28 Apr

20 Apr

17 Apr

6 Apr

2 Apr

1 Apr

31 Mar

26 Mar

25 Mar

23 Mar

19 Mar

12 Mar

10 Mar

6 Mar

26 Feb

Stockrow Weekly